Here we go again. Biotech stocks led Monday's market selloff, with the Nasdaq Biotech Index falling 4.1 percent following disappointing news from a pair of companies. Amgen Inc. led the stampede after FDA briefing documents posted Monday suggested its cancer immunotherapy drug, talimogene laherparepvec (T-vec), will face strong headwinds at Wednesday's joint meeting of the Cellular, Tissue and Gene Therapies and Oncologic Drugs Advisory Committee.